Skip to main content

Study of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus in Adults

Research Question:
Does the vaccine mRNA-1345 prevent RSV illnesses?

Basic Study Information

RSV is a virus that causes respiratory tract infections, which affect the lungs. RSV symptoms include runny nose, stuffy nose, wheezing, cough, sore throat, fever, and shortness of breath. RSV is the most common cause of severe lung infections and hospitalizations in young children and can cause lung infections in older adults. Both older adults with other health conditions, such as heart or lung disease, and adults who have received an organ transplant are at higher risk of serious illness from RSV infection. Vaccines help protect people from disease by causing the body to produce antibodies, which are proteins that fight off infection. There is currently no vaccine for RSV. This clinical trial is studying a new vaccine called mRNA-1345 to see if it can prevent RSV. You are eligible for this trial if you are 18–59 years old and have either diabetes, coronary artery disease, congestive heart failure, or lung disease. You are also eligible if you are >18 years old and have received an organ transplant more than 180 days ago.

Study Reference #: STUDY00008423

Lead Researcher (Principal Investigator)

Lead Researcher:  Ann Falsey

Study Contact Information

Study Coordinator: Katherine Elena
Phone: (585) 649-8760

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search